Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, whether he has had discussions with medical suppliers on the availability of Pancreatic Enzyme Replacement Therapy.
Answered by Karin Smyth
The Department continues to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to boost production to mitigate the supply issue. Suppliers have managed to secure additional pharmaceutical ingredient resulting in expected increased volumes of PERT for 2025. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the gap in the market and provided advice to clinicians on prescribing and ordering these imports.
In December 2024, the Department issued further management advice to healthcare professionals. This includes actions for clinicians to consider these unlicensed imports when licensed stock is unavailable and for integrated care boards to ensure local mitigation plans are put in place and implemented.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →